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Reactive oxygen species (ROS) can promote or inhibit tumorigenesis. In mesothelioma,
asbestos exposure to serous membranes induces ROS through iron content and
chronic inflammation, and ROS promote cell survival signaling in mesothelioma.
Moreover, a current chemotherapy regimen for mesothelioma consisting of a platinum
and antifolate agent combination also induce ROS. Mesothelioma is notoriously
chemotherapy-resistant, and we propose that ROS induced by cisplatin and pemetrexed
may promote cell survival signaling pathways, which ultimately may contribute to
chemotherapy resistance. In The Cancer Genome Atlas datasets, we found AXL kinase
expression is relatively high in mesothelioma compared to other cancer samples. We
showed that ROS induce the phosphorylation of AXL, which was blocked by the selective
inhibitor BGB324 in VMC40 and P31 mesothelioma cells. We also showed that cisplatin
and pemetrexed induce the phosphorylation of AXL and Akt, which was also blocked
by BGB324 as well as by N-acetylcysteine antioxidant. AXL knockdown in these cells
enhances sensitivity to cisplatin and pemetrexed. Similarly, AXL inhibitor BGB324 also
enhances sensitivity to cisplatin and pemetrexed. Finally, higher synergy was observed
when cells were pretreated with BGB324 before adding chemotherapy. These results
demonstrate cisplatin and pemetrexed induce ROS that activate AXL, and blocking AXL
activation enhances the efficacy of cisplatin and pemetrexed. These results suggest AXL
inhibition combined with the current chemotherapy regimen may represent an effective
strategy to enhance the efficacy of chemotherapy in mesothelioma. This is the first study,
to our knowledge, on chemotherapy-induced activation of AXL and cell survival pathways
associated with ROS signaling.
Keywords: AXL, reactive oxygen species, cisplatin, pemetrexed, mesothelioma, BGB324, chemotherapy
resistance
INTRODUCTION
Cellular oxidative stress is characterized by elevated reactive oxygen species (ROS), and is a frequent
phenotype of cancer cells (Szatrowski and Nathan, 1991; Luo et al., 2009; Oien et al., 2016).
High levels of ROS can disprupt critical functions of the cell by oxidizing proteins, nucleic acids,
and lipids (Oien and Moskovitz, 2008; Oien et al., 2009, 2010). These alterations are associated
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with both cancer initiation and tumor progression (Storz,
2005). However, elevated ROS also promote apoptosis (Watson,
2013). Several chemotherapy agents generate ROS, and increased
endogenous antioxidants often correlate with a reduction in
sensitivity to chemotherapy (Godwin et al., 1992; Ramanathan
et al., 2005; Berndtsson et al., 2007; Hwang et al., 2015). Since cells
have multiple antioxidant systems to counteract any perpetual
increases in ROS, we conceptualized blocking ROS-induced cell
survival signals as a method for enhancing the efficacy of current
chemotherapeutic agents.
Elevated ROS levels are associated with the phases of
mesothelioma progression, as well as non-surgical treatments
(Benedetti et al., 2015). Malignant pleural mesothelioma (MPM)
is a cancer in the serous membrane surrounding the lungs,
and has a very poor survival rate (Benedetti et al., 2015). The
rapid relapse of MPM tumors results in a progression-free
survival median of <6 months and overall survival median of
about 1 year (Bonelli et al., 2016). MPM is primarily caused
by asbestos exposure (Bonelli et al., 2016). The exposure of
asbestos to mesothelial cells generates ROS through iron content
and chronic inflammation (Benedetti et al., 2015; Pietrofesa
et al., 2016). This ROS may promote cell transformation,
such as through DNA damage, and also may promote cell
survival signaling (Clerkin et al., 2008; Benedetti et al., 2015).
Furthermore, standard chemotherapy agents used in MPM
treatment also generate ROS in addition to targeting DNA
mechanisms (Berndtsson et al., 2007; Hwang et al., 2015).
The lowMPM survival rate is attributed to late-stage diagnosis
and resistance to chemotherapy (Benedetti et al., 2015). A
platinum and antifolate drug combination are regularly used for
MPM chemotherapy treatment. Cisplatin is a platinum-based
drug that is activated upon entering cells, and promiscuously
binds nucleic acids and proteins (Akaboshi et al., 1992;
Berndtsson et al., 2007). DNA adducts caused by cisplatin
correlate with cell death, but at higher concentrations cisplatin
can generate ROS and cause acute apoptosis (Berndtsson et al.,
2007). Pemetrexed is an antifolate drug that interferes with
nucleic acid synthesis, generates ROS, and causes apoptotic cell
death (Hwang et al., 2015).
MPM cells are an ideal system to investigate the paradoxical
effect of ROS because ROS are implicated in the disease
promotion as well as in the response to chemotherapy. ROS
promote activation of several receptor tyrosine kinases (RTKs)
and inhibition of associated phosphatases (Rhee et al., 2003).
Several studies indicate RTKs are associated with MPM tumor
progression, including epidermal growth factor receptor (EGFR)
(Pache et al., 1998), vascular endothelial growth factor receptor
(VEGFR) (Ohta et al., 1999; Strizzi et al., 2001), insulin
growth factor 1 receptor (IGF1R) (Lee et al., 1993; Pass et al.,
2004), and AXL (Ou et al., 2011). We used the data from
The Cancer Genome Atlas (TCGA) to identify RTKs with
a relatively high expression in MPM, and chose to further
evaluate AXL. AXL promotes cell survival and proliferation
(Ou et al., 2011; Wu et al., 2014). Moreover, AXL activation
enhances chemotherapy resistance in lung cancer (Zhang et al.,
2012). AXL pathway activates anti-apoptotic mechanisms, for
example after vascular injury (Melaragno et al., 1998). AXL is
activated via phosphorylation (pAXL) by ROS and growth arrest
specific-6 (GAS6) (Konishi et al., 2004), and this phosphorylation
can induce the PI3K/Akt pathway (Huang et al., 2013). AXL
activation can be attenuated by inhibitors, and BGB324 is a first-
in-class small molecule inhibitor with selectivity to AXL (Holland
et al., 2010; Myers et al., 2016).
We hypothesize ROS, generated by cisplatin and pemetrexed,
induce the activation of AXL and cell survival pathway, which can
be blocked by AXL inhibitors to enhance the efficacy of current
MPM chemotherapy drugs. We demonstrate here that cisplatin
and pemetrexed generate ROS inMPM cells and induce AXL and
Akt phosphorylation. Blocking AXL activation with the BGB324
inhibitor enhances sensitivity to cisplatin and pemetrexed in
MPM cell lines. Finally, we show that higher sensitivity is
achieved when cells were pre-treated with BGB324 4 h prior to
chemotherapy.
MATERIALS AND METHODS
Reagents Stock Solutions
Cisplatin USP (Teva) was supplied as a 1 g/L solution in saline,
and pemetrexed (Sigma) was dissolved in water immediately
prior to use. BGB324 (Selleck Chemicals) was dissolved in
DMSO, and diluted in water immediately prior to use. Hydrogen
peroxide was diluted in water immediately prior to use from a
30 wt. % stock solution (Sigma). Solubility of all reagents were
visually verified in experimental systems prior to use.
RNA Expression in TCGA Samples
Data generated by the TCGA Research Network was used to
compare RNA expression and ranking among datasets. Values
and graphs for comparisons were obtained from cBioPortal
(Cerami et al., 2012; Gao et al., 2013).
Reverse Phase Protein Array and Cell Lines
Protein lysates from MPM cells lines were subjected to a reverse
phase protein array. This array was performed at the MD
Anderson Functional Proteomics RPPA Core Facility. MPM
cells lines used were SPC111, VMC14, VMC31, M38K, VMC40,
Meso53, SPC212, and P31 (Marklund et al., 1982; Pelin-Enlund
et al., 1990; Schmitter et al., 1992; Janson et al., 2008; Garay
et al., 2013; Schelch et al., 2014; Hoda et al., 2016). All cell
lines were maintained in Dulbecco Modified Eagle Medium
(GenClone) with 10% fetal bovine serum (Sigma). Lysates were
added to nitrocellulose-coated slides in five serial dilutions, and
subjected to 301 antibodies. Samples probed with antibodies
were analyzed by tyramide-based signal amplification approach,
and relative protein levels were determined after protein loading
normalization. These levels were fitted and analyzed by the
SuperCurve GUI method (Hu et al., 2007). The heat map was
generated in Cluster 3.0. Nonmalignant mesothelium Met-5a
cells (ATCC) were used for comparing basal AXL expression to
VMC40 and P31 cells, and in later cell death experiments.
Immunoblots and Antibodies
In six-well plates, 3.5 × 105 cells/well incubated at 37◦C
for overnight attachment prior to any treatment. Proteins
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were extracted from cells in 2x Laemmli buffer (Bio-Rad)
containing protease and phosphatase inhibitors. Except as
noted, equal sample volumes were applied to SDS-PAGE
gels and transferred to PVDF membranes. Membranes were
incubated in Odyssey Blocking Buffer (Li-Cor) overnight at
4◦C prior to probing with primary antibodies overnight at
4◦C. IRDye rabbit, mouse, and goat secondary antibodies (Li-
Cor) were applied to probed membranes for 45m at room
temperature, and visualized using a Li-Cor Odyssey scanning
system. Primary antibodies used for standard immunoblot
analysis included AXL (R&D Systems), pAktS473 and pan-
Akt (Cell Signaling Technology), and beta-actin (Sigma). Based
on minimal detection by standard methods, pAXLY702 (Cell
Signaling Technology), GAS6 (GeneTex), and beta-actin (as
system control) antibodies were used to detect corresponding
protein levels by Wes capillary electrophoresis (ProteinSimple)
based on the manufacturer’s protocol. Chemiluminescent signal
is depicted as traditional immunoblot protein bands, which
are generated by Compass software (ProteinSimple), as done
previously for RTKs (Furugaki et al., 2016).
ROS Detection
In six-well plates, 3.5 × 105 cells/well incubated at 37◦C for
overnight attachment. Medium was removed from each well,
and 5µM chloromethyl-dihydrogen-2
′
,7
′
-dichlorofluorescein
diacetate (CM-H2DCFDA)was added to each well for 20m. After
incubation, cells were lifted with trypsin (Sigma) and transferred
to centrifuge tubes. Tubes were centrifuged, supernatant
aspirated, and fresh medium premixed with indicated reagent(s)
was added. Cells were incubated for 30m at 37◦C with gentle
shaking. Prior to analysis, propidium iodide was added at a final
concentration of 1.3µg/mL to reduce dead cells during analysis
through gating. Fluorescence in cells was detected with a LSR II
flow cytometer (BD Biosciences) using FITC filters.
Caspase 3 Activity Assay
Caspase 3 activity was measured using the DEVD-AFC (Asp-
Glu-Val-Asp, 7-amino-4-trifluoromethylcoumarin) fluorescent
assay as we have previously described (Bastola et al., 2016).
Briefly, cells were prepared as done for immunoblots and lysed
using CHAPS lysis buffer (20mM PIPES, 100mM NaCl, 1mM
EDTA, 0.1% (w/v) CHAPS, 10% sucrose, 10mM DTT pH
7.2). Protein concentration was determined using the Pierce
BCA Assay (Thermo Fisher). Twenty milligrams of protein was
combined with 2 µL of 2mM DEVD-AFC (Millipore) in 96-well
flat-bottom plates. Two hundred microliters/well lysis buffer was
added. The plate was covered and incubated at 37◦C. After 2 h,
fluorescence measurements were taken at Ex 400 nm and Em
510 nm using a Synergy4 plate reader (BioTek).
AXL Knockdown
VMC40 and P31 cells with AXL shRNA were generated
using human GIPZ lentiviral shRNAmir individual clones
(Dharmacon) according to the manufacturer’s protocol.
Transfected cells were selected in puromycin for 2 weeks prior to
use. Knockdownwas determined by immunoblots usingmethods
described above using three different gel loading volumes for
estimation of shRNA efficacy compared to nontargeting control
(NTC). Cell proliferation was determined by the sulforhodamine
B (SRB) assay by plating equal cells, 5,000 cells/well in 96-well
plates, and incubating for 4 days. Quantification with SRB stain
was done as described below, based on our previous methods
(Bastola et al., 2016).
SRB Survival Assays and Drug Synergy
Calculations
Short-term SRB survival assays and synergy calculations were
performed as previously described (Bastola et al., 2016). Briefly,
5,000 cells were plated in 96-well plates and attached by
overnight incubation. The following day, cells were treated
with different concentrations of BGB324 and cisplatin or
pemetrexed, and in combinations as indicated. After 72 h, cells
were fixed with 10% trichloroacetic acid (Sigma). Fixed cells
were washed with tap water and stained using SRB (Sigma) at
room temperature for 45m. Cells were washed with 1% acetic
acid solution, and then were dissolved in 10mM Tris, pH 10,
and fluorescence measurements were taken at Ex 488 nm and
Em 585 nm using a Synergy4 plate reader. Where specified,
the concentration that causes 50% growth inhibition (GI50)
was estimated using Prism software (GraphPad). Drug synergy
was determined by calculating the combination indices (CIs)
obtained from the fluorescence measurements. The CI values
were calculated based on dividing the combination expected
effect by the observed effect: CI = (D1 +D2
∗(1-D1))/Dobserved,
where D represents the cell death from drug 1, drug 2, and
the combination (observed) (Bastola et al., 2016). The mean
CI values were determined from multiple drug combinations
in duplicates that produced 20–80% effect from independent
experiments.
Clonogenic Cell Death Assays
Long-term survival assays were performed as previously
described (Bastola et al., 2016). Briefly, 500 cells/well were
plated in 6-well plates and cells were attached by overnight
incubation. Regents were added to cells and incubated for
72 h. Following treatment, medium was gently aspirated and
replaced with regular growth medium. Cells were then incubated
for 4–7 additional days. Once the colonies were optimal for
visualization, cells were fixed with 10% trichloroacetic acid.
Fixed cells were washed with tap water and stained using
SRB at room temperature for 45m. Cells were then washed
with 1% acetic acid solution. The plates were air-dried, and
pictures were taken using the Bio-Rad Imager System. For
quantification, stained cells were dissolved in 10mM Tris, pH 10
and the solution was transferred to 96-well plates for fluorescence
measurement.
Analyses and Statistics
Densitometry values from immunoblots were determined by
Image Studio software (Li-Cor). Dose-response data and non-
linear regression curves were generated using Prism software. Bar
charts were generated via Excel (Microsoft), and t-test statistical
analyses used with a significance threshold of p < 0.05.
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RESULTS
AXL Expression Is Elevated in MPM
To uncover RTKs that may be promoting MPM cell survival, the
expression levels of common RTKs were ranked based on the
expression among the 30 TCGA datasets accessed through the
cBioPortal bioinformatics web tool (Cerami et al., 2012; Gao
et al., 2013). AXL expression was the fourth highest in MPM
samples among other cancer types, with a mean log2 value of
11.40 (Figure 1A and Supplementary Figure 1). This expression
value for AXL was higher than IGF1R (11.04), EGFR (10.14), and
the other “TAM” kinases Tyro3 and Mer. The VEGFR1 kinase
expression was higher than AXL in MPM, however, the VEGF
ligand (VEGFA gene) was not expressed in MPM as high as most
other cancers in the dataset (ranking #20 of 30). The AXL ligand,
GAS6, had the third highest expression in MPM, versus the other
cancer datasets, with a mean log2 value of 13.06 (Figure 1A and
Supplementary Figure 2). Moreover, AXL was demonstrated in
prior studies to regulate MPM proliferation (Ou et al., 2011),
and ROS was shown to activate AXL and increase GAS6 binding
(Konishi et al., 2004). Based on literature, and AXL and GAS6
expression in MPM, the AXL kinase was selected for further
study.
Eight MPM cell lines were used in a reverse phase protein
array to detect differences in protein expression including AXL
(Figure 1B and Supplementary Figure 3). Of these cell lines, AXL
expression was highest in VMC40 cells (normalized log2 median-
centered value of 1.35), and P31 cells had AXL expression near
the median (−0.07). The immunoblot analysis confirmed that
AXL expression and phosphorylation were higher in VMC40
than the nonmalignant mesothelial cell line Met-5a (Figure 1C).
In addition, GAS6 expression was also higher in VMC40 than
in Met-5a cells. These results suggest autocrine AXL pathway is
active in MPM cells.
Cisplatin and Pemetrexed Generate ROS
Cisplatin and pemetrexed each have been shown previously to
induce elevated ROS in cells (Berndtsson et al., 2007; Hwang
et al., 2015), but have not been evaluated for cellular ROS
increases as a combination. Cisplatin can induce detectable
ROS increases in melanoma cells at concentrations of 10 and
20µM, measured at 3 h (Berndtsson et al., 2007). However, at
MPM clinical doses (e.g., 75 mg/m2) plasma concentrations of
cisplatin is below 20µM (Andersson et al., 1996). In contrast,
MPM pemetrexed doses of 500 mg/m2 can achieve Cmax values
near 250µM (Sweeney et al., 2006). Moreover, pemetrexed
could induce ROS at a concentration of 2µM in MPM cells,
measured at 24 h (Hwang et al., 2015). In both VMC40 and
P31 cells, higher concentrations of cisplatin (7.5 and 15µM),
multiple concentrations of pemetrexed (2, 4, and 8µM), and
multiple concentrations of combined cisplatin and pemetrexed
(3.8/2, 7.5/4, and 15/8µM, respectively) induced significant
increases in ROS after 30m versus control cells when using
the CM-H2DCFDA indicator (Figure 2). The combination of
15µM cisplatin and 8µM pemetrexed produces significantly
higher ROS than cisplatin alone (p = 0.049 and 0.047 for
VMC40 and P31, respectively), but not significantly different
from pemetrexed alone.
FIGURE 1 | AXL is abnormally expressed in MPM. (A) AXL and GAS6
expression are elevated in clinical MPM samples. Of 30 TCGA cancer
datasets, MPM (87 samples, blue dots) ranked fourth highest for AXL and
third highest for GAS6 expression, and mean log2 values were 11.40 and 13.06,
(Continued)
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FIGURE 1 | respectively. Data are RNA Seq V2 values from TCGA Research
Network. (B) Reverse phase protein heat map subset with AXL. MPM cell
extracts applied to coated slides and probed with 301 antibodies, normalized
to loading. Color brightness indicates protein detection relative to median, red
for increased and green for decreased detection levels. Normalized log2
median-centered value of AXL was 1.35 for VMC40. (C) Lysates analyzed for
pAXL and GAS6 ligand using capillary electrophoresis, and other proteins were
detected by standard immunoblot methods. Met-5a as a nonmalignant
mesothelial control cell line for comparison. Densitometry values are relative to
corresponding protein of Met-5a, normalized to respective ß-actin loading
control.
Cisplatin and Pemetrexed Can Activate
AXL
Prior studies have shown AXL can be phosphorylated by
hydrogen peroxide (Konishi et al., 2004), but it has not been
evaluated if chemotherapy agents can activate AXL. Based on
our observation that chemotherapy agents increase ROS levels
(Figure 2), VMC40 and P31 MPM cells were treated with 15µM
cisplatin and 8µMpemetrexed for short (minutes) and relatively
long (6 h) time points. Increases in AXL phosphorylation were
detected after 10m of exposure to cisplatin and pemetrexed
(Figures 3A,B, Supplementary Figure 4A). Consistent with prior
studies indicating that AXL inhibitor BGB324 attenuates ROS-
induced phosphorylation of AXL (Smolock and Korshunov,
2010), AXL phosphorylation was blocked when MPM cells
were co-treated with BGB324. Again, consistent with prior
studies indicating that pro-survival kinase Akt1 was activated
downstream of AXL (Huang et al., 2013), both cisplatin and
pemetrexed induce Akt phosphorylation of S473 at variable
time points. Akt phosphorylation was blocked by BGB324. The
pAkt levels did not change from adding BGB324 inhibitor
alone compared to no treatment (Supplementary Figure 4B),
suggesting that BGB324 does not inhibit Akt directly. In
parallel, cells treated with 150µM hydrogen peroxide show
AXL and Akt phosphorylation, and this phosphorylation was
blocked by BGB324 (Figure 3C). Cells co-treated with 4mM
N-acetylcysteine antioxidant did not show an increase in AXL
and Akt phosphorylation (Figure 3D). Collectively, these results
suggest cisplatin and pemetrexed induce ROSwhich then activate
AXL and downstream Akt. Finally, this signaling cascade can be
blocked by BGB324 or N-acetylcysteine.
Based on the phosphorylation of Akt, we next determined
changes in downstream caspase-3 activity with and without
BGB324 after 24 h of chemotherapy exposure (Figure 3E). The
presence of BGB324 significantly increased the caspase-3 activity
in cells treated with cisplatin and pemetrexed. Overall, these
results indicate the possibility that BGB324 could enhance the
cytotoxicity of these chemotherapy agents in VMC40 and P31.
AXL Knockdown Enhances Cisplatin and
Pemetrexed Sensitivity
Based on the results that cisplatin and pemetrexed enhance
pAXL and pAkt (Figure 3), we hypothesized AXL inhibition
may enhance sensitivity to these chemotherapy agents. AXL
was knocked down via AXL shRNA in both VMC40 and P31
cells (Figure 4A). AXL knockdown efficiency was estimated
by immunoblots using loading volumes of 5, 15, and 30 µL.
Detected AXL of VMC40 cells averaged 37.7% for shRNA#1
and 36.1% for shRNA#2 compared to NTC controls, and of
P31 cells averaged 33.0% for shRNA#1 and 28.4% for shRNA#2.
The AXL shRNA decreased cell proliferation (Figure 4B). Using
the SRB assay and comparing to NTC, cells with AXL shRNA
were more sensitive to cell death at increasing concentrations of
cisplatin and pemetrexed (Figure 4C, Supplementary Figure 5).
To analyze the drug response following AXL knockdown, drug
response was compared at each concentration respective to the
absence of drug. A significant decrease in cell survival was
observed in AXL knockdown cells compared to NTC at 1.88
and 15µM for cisplatin in VMC40 cells, and at 1 and 8µM
for pemetrexed in both VMC40 and P31 cells (Supplementary
Figure 5). Consequently, we verified these results using secondary
long-term clonogenic assays where the drug is washed out after
72 h (Figure 4D and Supplementary Figure 6). These data suggest
AXL may be targeted to enhance sensitivity to cisplatin and
pemetrexed.
Blocking AXL Activation Enhances
Cisplatin and Pemetrexed Efficacy
Building upon the observation that AXL knockdown enhances
sensitivity to cisplatin and pemetrexed, we next evaluated
if inhibiting AXL phosphorylation would result in enhanced
sensitivity to cisplatin and pemetrexed. The selective AXL
inhibitor, BGB324, has been studied as a monotherapy and with
other chemotherapeutic agents (Holland et al., 2010; Wnuk-
Lipinska et al., 2014; Wang et al., 2016). We used the SRB assay
to determine the extent of cytotoxicity induced by BGB324 in
the presence of incrementing concentrations of cisplatin and
pemetrexed (Figure 5A and Supplementary Figure 7). In these
SRB assays, combined effects of BGB324 with cisplatin and
pemetrexed weremostly additive with CI values of approximately
1 (Figure 5B). CI values <1 indicate synergistic effects, while
values >1 indicate antagonistic effects. In contrast, the addition
of BGB324 did not have a significant effect on GI50 values
with incrementing concentrations of cisplatin and pemetrexed
in nonmalignant Met-5a cells (Figure 5C). To further validate
results from VMC40 and P31 SRB assays, we performed
clonogenic assays in these cell lines (Figures 5D,E). Both cell
lines showed increased cell death at relatively low concentrations
compared to SRB assays, suggesting a fraction of cells surviving
in SRB assays could be in senescence. Moreover, mean CIs from
the clonogenic assay were 0.95 for 1.4µM cisplatin with BGB324
and 0.91 for 0.1µM pemetrexed with BGB324 in VMC40 cells,
which suggests marginal synergistic cytotoxicity. For P31 cells,
the mean CIs for concentrations shown were 0.93 for cisplatin
with BGB324 and 1.02 for pemetrexed with BGB324.
The mainly additive drug-drug interaction between BGB324
and cisplatin or pemetrexed raises the question if the sequence of
drug exposure must be optimized. We performed essentially the
same assays in Figure 5, except the BGB324 inhibitor was added
4 h prior to any addition of cisplatin and pemetrexed (Figure 6).
In SRB assays, cell death was enhanced when pre-treatment of
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FIGURE 2 | Cisplatin and pemetrexed induce ROS generation. The CM-H2DCFDA ROS indicator was preloaded into (A) VMC40 and (B) P31 cell lines, followed by
30m of cisplatin and pemetrexed treatment. Fluorescent signal was detected by flow cytometry, and area-under-curve values were compared to untreated samples
as percentages. Representative histograms of combined cisplatin and pemetrexed concentrations on right. Error bars represent ±SEM of three experiments. * and †
denote p < 0.05 via t-test for value compared to untreated control and to drug combination, respectively.
BGB324 was added to incrementing concentrations of cisplatin
and pemetrexed (Figure 6A and Supplementary Figure 8).
Calculated CI means for these combinations suggest more cell
death synergy for both VMC40 and P31 cells (Figure 6B),
compared to when agents were added to cells at the same time
(Figure 5B). In Met-5a cells, adding BGB324 as a pretreatment
did not significantly alter the GI50 values for cisplatin and
pemetrexed. The SRB results for VMC40 and P31 cells were
validated using clonogenic assays (Figures 6D,E). The mean
CIs from the clonogenic assay were 0.91 for 1.4µM cisplatin
with BGB324 and 0.74 for 0.1µM pemetrexed with BGB324 in
VMC40 cells, suggesting synergistic cytotoxicity. For P31 cells,
the mean CIs at concentrations shown were 0.88 for cisplatin
with pretreated BGB324 and 0.94 for pemetrexed with pretreated
BGB324.
The combination of cisplatin and pemetrexed are the current
chemotherapy for MPM (Benedetti et al., 2015; Yap et al., 2017).
As a proof-of-concept, we performed clonogenic assays using
this combination (at half the concentrations used previously
in Figures 5D,E, 6D,E) with BGB324 (Figure 7A). Also, we
performed the essentially the same assay with BGB324 being
added 4 h prior to chemotherapy agents (Figure 7B). These
results were quantified by solubilizing and measuring the stain
(Figure 7C). For VMC40 cells, the mean CIs were 0.91 for
co-treatment with BGB324 and 0.74 for pretreated with BGB324,
indicating synergistic cytotoxic effects. For P31 cells, the mean
CIs were 1.04 for co-treatment with BGB324 and 0.92 for
pretreatment with BGB324.
DISCUSSION
Prior evidence of elevated cellular ROS promoting cell survival
(Clerkin et al., 2008; Niederst and Engelman, 2013) led to the
hypothesis that chemotherapy-induced ROS may also promote
these signaling pathways, and inhibiting these pathways may
enhance chemotherapy efficacy. In MPM cells, we showed
that cisplatin and pemetrexed induce ROS (Figure 2), and
phosphorylate AXL and Akt (Figure 3). Moreover, knocking
down AXL or blocking AXL activation with BGB324 enhances
sensitivity to cisplatin and pemetrexed (Figures 4–7).
Based on these results, we propose a model where the
effects of ROS promoting cell survival and apoptosis are in
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FIGURE 3 | Cisplatin and pemetrexed promote phosphorylation of AXL and downstream Akt. (A–C) Time course of pAXL and downstream pAkt detection in the
presence of (A) 15µM cisplatin, (B) 8µM pemetrexed, and (C) 150µM H2O2. Phosphorylation of AXL was inhibited by adding 2µM BGB324. Densitometry values
as percentage of untreated control are shown for pAXL and pAkt, normalized to respective beta-actin. (D) pAXL detection with the addition of 4mM N-acetylcysteine
(NAC) antioxidant at 60m. Lysates (A–D) were analyzed for pAXL using capillary electrophoresis, and other proteins were detected by standard immunoblot methods.
Densitometry values are relative to corresponding protein of untreated control, normalized to respective ß-actin loading control. (E) Caspase 3 activity after 24 h of
indicated drug treatment. Error bars represent ±SEM of three experiments. * and † denote p < 0.05 via t-test for value compared to untreated control and to drug
combination, respectively.
a balance (Figure 8). Cisplatin and pemetrexed both induce
ROS generation that contributes to cytotoxicity (Berndtsson
et al., 2007; Watson, 2013; Hwang et al., 2015), and ROS
levels are elevated in MPM cells after 30m of treatment
with cisplatin or pemetrexed (Figure 2). We showed that
these agents induce AXL phosphorylation, which is blocked
by the addition of BGB324 inhibitor and N-acetylcysteine
antioxidant (Figure 3), suggesting that chemotherapy-induced
ROS mediate AXL activation. Cisplatin and pemetrexed also
induced phosphorylation of Akt (Figure 3), which may promote
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FIGURE 4 | AXL knockdown enhances cisplatin and pemetrexed efficacy. (A) Relative quantification of AXL after shRNA AXL knockdown using three gel loading
volumes of 5, 15, and 30 µL. Values are percentage of NTC. (B) Cell proliferation via SRB assay, values compared as percentage to NTC after 4 days of plating equal
cell numbers. *Denotes p < 0.05 via t-test for value compared to NTC value. (C) Cell survival percentages by SRB assay after 72 h treatment with cisplatin (top) and
pemetrexed (bottom) at incrementing concentrations. (D) Cell survival percentages by clonogenic assay after 72 h treatment with cisplatin (top) and pemetrexed
(bottom) at incrementing concentrations. Values are relative to no drug treatment (100% for both NTC and AXL shRNA).
†
Denotes p < 0.05 via t-test for value
compared to NTC value at the same concentration. Error bars represent ±SEM of three experiments (B-D).
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FIGURE 5 | Combination of BGB324 with cisplatin and pemetrexed enhances MPM cell death. (A) Cell survival for incrementing concentrations of cisplatin and
pemetrexed with and without 0.5µM BGB324. Values determined by SRB assay at 72 h. Actual values, dose-response curve of BGB324, and statistical analysis at
specified concentrations are shown in Supplementary Figure 7. (B) CI range (gray box) and mean (black line) from full data shown in Supplementary Figure 7A. The
reference value, 1.00, is indicated by a blue line. CI < 1.00 is considered synergistic. CI values calculated as described in section Materials and Methods. (C) GI50
values for cisplatin and pemetrexed in nonmalignant Met-5a cells. (D) Representative images of clonogenic assays after 72 h treatment and then allowing cells to form
colonies in absence of drugs. (E) Quantification of clonogenic assays.
†
Denotes p < 0.05 via t-test for value compared to values of single agents. Error bars represent
±SEM of three experiments (A,C,E).
cell survival signaling (Clerkin et al., 2008; Hong et al., 2008).
We showed that ROS-induced Akt phosphorylation is mediated
through AXL because BGB324 attenuates ROS-induced Akt
phosphorylation. In addition, we showed that chemotherapy-
induced Akt phosphorylation is in part mediated through AXL
because BGB324 partially attenuated Akt phosphorylation.
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FIGURE 6 | Time-sequenced BGB324 combination with cisplatin and pemetrexed enhances MPM cell death. BGB324 was added 4 h before other drugs. (A) Cell
survival for incrementing concentrations of cisplatin and pemetrexed with and without 0.5µM BGB324. Values determined by SRB assay at 72 h. Actual values,
incrementing concentrations of BGB324, and statistical analysis at specified concentrations are shown in Supplementary Figure 8. (B) CI range (gray box) and mean
(black line) from full data shown in Supplementary Figure 8A. The reference value, 1.00, is indicated by a blue line. CI < 1.00 is considered synergistic. CI values
calculated as described in section Materials and Methods. (C) GI50 values for cisplatin and pemetrexed in nonmalignant Met-5a cells. (D) Representative images of
clonogenic assays after 72 h treatment and then allowing cells to form colonies in absence of drugs. (E) Quantification of clonogenic assays.
†
Denotes p < 0.05 via
t-test for value compared to values of single agents. Error bars represent ±SEM of three experiments (A,C,E).
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FIGURE 7 | Combination of BGB324 with both cisplatin and pemetrexed. (A) Representative images of clonogenic assays after 72 h treatment with BGB324,
cisplatin, and pemetrexed. (B) Representative images of clonogenic assays after 4-h pretreatment with BGB324 followed 72 h treatment with both cisplatin and
pemetrexed. (C) Quantification of (A,B) by measuring quantity of stain from cells.
†
Denotes p < 0.05 via t-test for value compared to values of BGB324 alone. Error
bars represent ±SEM of three experiments.
We investigated AXL activation using 150µM H2O2, which
is a level of ROS consistent with moderate cellular oxidative
stress (Ravid et al., 2002; Pal et al., 2007; Oien and Moskovitz,
2008; Oien et al., 2010). For activating AXL using cisplatin and
pemetrexed, we used drug concentrations that resulted in similar
CM-H2DCFDA fluorescence as 150µM H2O2 at 30m. Using
SRB assays, we show pretreatment with 0.5µM BGB324 can
enhance cytotoxicity from 15µMcisplatin and 8µMpemetrexed
at 72 h (Figures 6A,B, Supplementary Figure 8). Initially, we
used the same drug concentrations for 72 h treatment in the
clonogenic assay, which resulted in a very minimal quantity of
cells producing colonies, even with monotherapy treatment (data
not shown). It is interesting that much lower drug concentrations
in the clonogenic assay still result in significant cytotoxicity
increases when BGB324 is added to cisplatin and pemetrexed
(Figures 6D,E). This could indicate cellular ROS is generated by
these lower concentrations of cisplatin and pemetrexed over a
longer time period, but this still remains to be investigated for
both monotherapies and combination therapy.
The Akt pathway can regulate the viability of cells through
manipulation of apoptosis-associated molecules or by regulating
key apoptosis transcription factors (Clerkin et al., 2008). It is not
known if the Akt pathway counteracts ROS-induced apoptosis
in our system, but it is likely these opposing pathways are
influencing a balance between apoptosis and survival. In support
of this concept, we have shown that AXL knockdown enhances
sensitivity cisplatin and pemetrexed (Figure 4), suggesting
that chemotherapy-induced AXL activation is an adaptive
response that may blunt the cytotoxic effect of chemotherapy.
Accordingly, AXL inhibitor BGB324 blocks the adaptive response
mediated by AXL and enhances sensitivity to cisplatin and
pemetrexed (Figure 5). It appears that pretreatment with
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FIGURE 8 | Known pathways and hypothesis for AXL inhibitor (red box) and
platinum or antifolate drug (blue box) synergies. Black arrows: Activated AXL
promotes cell survival. ROS can increase GAS6 activation and activate AXL
independently. Cisplatin and pemetrexed cause cell cycle arrest and increased
ROS promoting apoptosis, but ROS-induced AXL activation can inhibit
apoptosis. Red line: AXL inhibition can decrease cell survival and promote
apoptosis. We have shown adding an AXL inhibitor to current chemotherapy
will synergistically promote cell death. This synergy is based on inhibiting an
opposing pathway of apoptosis.
BGB324 enhances the sensitivity to cisplatin and pemetrexed
more than co-treatment with BGB324 (Figure 6), but further
investigation is needed to understand the molecular mechanisms
contributing to synergism between pre-treatment with BGB324
and chemotherapy. Moreover, it would be important to evaluate
the dynamic effects of endogenous antioxidants/antioxidant
capacity in this system, especially over longer treatment periods
of time and in chemotherapy-resistant cells.
The biochemical mechanism of ROS regulating AXL is
unknown. ROS activation of AXL could be direct, through
another kinase, or inhibiting an unknown phosphatase (Huang
et al., 2013). No direct oxidation of AXL has been reported,
however, a similar region in EGFR has been shown to be oxidized
with increased phosphorylation (Truong and Carroll, 2012).
Furthermore, any direct interaction between AXL and PI3K/Akt
has not been reported to our knowledge, and investigation of this
pathway may lead to valuable drug target insights.
AXL is activated though autocrine/paracrine signaling by the
GAS6 ligand, and this complex is degraded in the lysosome
following endocytosis (Wu et al., 2014). The E3 ubiquitin ligase
c-Cbl binds AXL, and ubiquitination is required for degradation
in the lysosome (Valverde, 2005). AXL is also activated by ROS
independent of ligand (Konishi et al., 2004). In the presence
of ROS, AXL ubiquitination is reduced, which results in an
increased duration of pAXL (Valverde, 2005). Activation of
a structurally similar receptor tryrosine kinase, EGFR, in the
presence of ROS promotes accumulation on the cell membrane,
but this effect has not been studied for AXL (Ravid et al.,
2002). EGFR is aberrantly phosphorylated and degradation is
reduced in the presence of hydrogen peroxide (Filosto et al.,
2011). Evidence also supports that cysteine oxidation in the ATP-
binding region promotes phosphorylation of EGFR (Truong
and Carroll, 2012). Moreover, IGF1R is rapidly expressed and
activated in the presence of hydrogen peroxide, and inhibition
of this receptor has been shown to promote apoptosis (Azar
et al., 2007; Baregamian et al., 2012). Several reports of AXL
phosphorylation have demonstrated this to be fast and quickly
degraded (Valverde, 2005; Bae et al., 2015). Therefore, changes in
redox biology induced by chemotherapy likely contribute to AXL
activation and adaptive response mediated by AXL.
Adaptive cellular response to chemotherapy plays an
important role in providing the cells with transient resistance
to chemotherapy and may ultimately contribute to the acquired
chemotherapy resistance (Goldman et al., 2015). Therefore, our
discovery of AXL-mediated adaptive response and our finding
that AXL inhibition enhances sensitivity to chemotherapy
is significant. In summary, we show here that cisplatin and
pemetrexed can activate AXL, which can be blocked by the
BGB324 AXL inhibitor. Adding BGB324, especially as a
pretreatment, can enhance the cell death efficacy of cisplatin and
pemetrexed in MPM cells. These studies may support future in
vivo investigations on the ability of BGB324 to enhance cisplatin
and pemetrexed tumor reduction.
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